The efficacy and safety of strontium ranelate versus placebo in the treatment of knee osteoarthritis

The efficacy and safety of two doses of strontium ranelate versus placebo administered orally for 3 years in the treatment of knee osteoarthritis: a prospective multicentre, international, double-blind, placebo-controlled study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN92624244

Enrollment

450

Registered

2010-04-14

Start date

2008-06-30

Completion date

Unknown

Last updated

2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis Musculoskeletal Diseases Polyarthrosis

Interventions

The treatment is composed of two doses of strontium ranelate (1 g and 2 g per day) administered orally for 3 years.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Asia men and women of at least 50 years of age 2. Primary knee osteoarthritis

Exclusion criteria

Exclusion criteria: 1. Knee prosthesis already implanted or foreseen within the next year 2. Hip prosthesis recently implanted (less than 1 year) or not well-tolerated, or foreseen within the next year

Design outcomes

Primary

Measure	Time frame
Radiographic assessment of knee osteoarthritis measured up to 36 months	—

Secondary

Measure	Time frame
Measured up to 36 months: 1. Algofunctional assessment 2. Physical examination 3. Safety	—

Countries

China, Korea, South, Taiwan

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026